InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,244.80
(
0.27%
)
Dow Jones
39,872.99
(
0.17%
)
Brent Oil
82.06
(
-0.47%
)
Bitcoin
69,819.79
(
-0.44%
)
Post# of 251888
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 171131

Wednesday, 12/11/2013 5:37:04 AM

Wednesday, December 11, 2013 5:37:04 AM

Post# of 251888

TEVA’s PR on its bifurcated 2014 guidance (i.e. with and without generic Copaxone in the US):

TEVA is expecting to lose $0.5B in 2014 from orals competition and about another $0.5B from generics (they assumed 2) if approved in mid 2014.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up